Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Robert Haussmann1, Maria Buthut2, Markus Donix1,3

  • 1Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Pharmacopsychiatry
|May 19, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune-proteo-metabolomic changes link to Aβ and tau pathology in Alzheimer disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Gait dysfunction as an early marker of phenoconversion in REM sleep behavior disorder.

Scientific reports·2026
Same author

Frequency of autoimmune-associated exogenous psychoses in routine clinical care.

Brain, behavior, & immunity - health·2025
Same author

Frequency of synaptic antigen-specific CD4<sup>+</sup> T cells in dementia is age-dependent but not correlated with cognitive impairment.

Immunity & ageing : I & A·2025
Same author

Anti-VGLUT2 autoantibodies in neurological diseases.

Brain, behavior, and immunity·2025
Same author

Overlapping presence of β-amyloid, tau, p-tau, and α-synuclein in skin nerve fibers in Alzheimer's disease.

Journal of neurology·2025
Same journal

A Tribute to Prof. Jules Angst highlighting his Contributions to Clozapine.

Pharmacopsychiatry·2026
Same journal

Correction: Escitalopram and Clonazepam Affect Gasotransmitter-related Enzyme (nNOS, HO-2, CBS) Gene Expression in the Rat Brain.

Pharmacopsychiatry·2026
Same journal

Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

Pharmacopsychiatry·2026
Same journal

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same journal

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

Pharmacopsychiatry·2026
Same journal

A Naturalistic Study on the Cost Reduction and Efficacy of Long-acting Antipsychotics in an Early Intervention Programme for Patients with Recent-onset Psychosis.

Pharmacopsychiatry·2026
See all related articles

Assessing driving ability in older adults and those with cognitive impairment is crucial. Reliable evaluation requires comprehensive assessments, including neurocognitive tests and on-the-road evaluations, to avoid unnecessary driving restrictions.

Area of Science:

  • Gerontology
  • Neuroscience
  • Transportation Safety

Background:

  • Driving ability is critical for independence in the elderly and cognitively impaired.
  • Normal aging may impact driving skills, but findings are debated due to potential biases.
  • Mild cognitive impairment and dementia lead to irreversible driving ability loss.

Purpose of the Study:

  • To highlight the complexity of driving challenges in an aging population.
  • To increase awareness regarding the need for accurate driving ability assessments.
  • To discuss the importance of avoiding unnecessary driving restrictions.

Main Methods:

  • Comprehensive specialist assessment is required for reliable evaluation.
  • Neurocognitive evaluation is a key component of driving ability assessment.

Related Experiment Videos

  • On-the-road testing and medical history review are essential.

    • Main Results:

    • Older drivers' performance compared to younger drivers is inconsistent across studies.
    • Some research indicates a decline in driving ability with normal aging.
    • Evidence suggests the need for careful, individualized driving assessments.

    Conclusions:

    • Accurate assessment of driving ability in the elderly and cognitively impaired is vital.
    • A multi-faceted approach including neurocognitive and on-road testing is necessary.
    • Preventing unwarranted driving restrictions requires reliable and thorough evaluations.